Market Overview

UPDATE: Piper Jaffray Upgrades Amgen to Overweight on Continued Upside

Related AMGN
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
Don't Bail On Biotech ETFs: 'There Are Several Reasons Why The Sector Took A Breather'
FDA OKs Sun Pharma's Ilumya for plaque psoriasis (Seeking Alpha)

Piper Jaffray upgraded its rating on Amgen (NASDAQ: AMGN) from Neutral to Overweight and increased its price target from $77 to $95.

Piper Jaffray commented, "We are upgrading AMGN to OW from Neutral and raising our price target to $95 from $77 following 2Q earnings that provided strong evidence of stabilization of the company's base businesses. In addition, the company announced advancement of three products into Phase III trials, two of which could be potential blockbusters (AMG145 and AMG785), that should drive long term growth. This combined with renewed fiscal discipline and willingness to increase dividend yield in line with major pharmaceutical companies should enable AMGN shares to continue to outperform."

Amgen closed at $77.96 on Thursday.

Latest Ratings for AMGN

Feb 2018Atlantic EquitiesDowngradesOverweightNeutral
Feb 2018Credit SuisseMaintainsNeutralNeutral
Feb 2018BMO CapitalMaintainsMarket PerformMarket Perform

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (AMGN)

View Comments and Join the Discussion!